Review

Telaprevir and Boceprevir in African Americans with Genotype 1 Chronic Hepatitis C: Implications for Patients and Providers

Telaprevir and boceprevir have received US Food and Drug Administration approval for use as triple therapy with pegylated interferon and ribavirin in genotype 1 chronic hepatitis C virus (HCV) infection. Clinical trials of these agents included few African Americans, despite the overwhelming need for improved therapies in this racial group….